Catalog No.
Product Name
Application
Product Information
Citations
-
β-Catenin/Tcf Inhibitor
FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
-
Wnt inhibitor
IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription.- Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921
-
Wnt/beta-catenin inhibitor
ICG-001 is a specific inhibitor of Wnt/β-catenin signaling pathway that inhibits β-catenin/cyclic AMP response element-binding (CREB) protein transcription (IC50=3 microM) .- Hong Gao, .et al. , Sci Rep, 2024, Oct 15;14(1):24182 PMID: 39406776
- Yun-Sheng Chen, .et al. , Research Square, 2024, August 16th
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Seonmin Choi, .et al. , Yonsei Med J, 2021, Nov;62(11):1042-1051 PMID: 34672138
- Jasper C.Munro, .et al. , Livest Sci, 2019, 229 (2019) 159-169
- Kim JH, .et al. , Cell Rep, 2019, May 14;27(7):2105-2118.e5 PMID: 31091449
- Yamaoka R, .et al. , J Surg Oncol, 2018, Sep;118(4):664-674 PMID: 30196535
- Aida Y, .et al. , In Vitro Cell Dev Biol Anim, 2018, Jun;54(6):468-476 PMID: 29785536
-
beta-catenin inhibitor
BC2059 is an orally bioavailable and potent beta-catenin inhibitor.- Ji-Hye Jung, .et al. , Stem Cells Dev, 2016, Jul 1; 25(13): 1006-1019 PMID: 27188501
-
CBP/beta-catenin antagonist
PRI-724 is the second-generation, potent and specific inhibitor of CBP/β-Catenin complex, and a modulator of the β-Catenin dependent canonical Wnt signaling pathway in cancer stem cells.
- Paul Mark Medina, .et al. , Transl Oncol, 2021, Jan;14(1):100940 PMID: 33221682
- Prodigiosin (Prodigiosine) is a secondary metabolite of Symbiotic bacteria, with anti-fungal and anti-cancer activity.
-
sFRP-1 inhibitor
WAY-316606 is a small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. -
Bcl-2 Family activator
(E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls. (E)-Ferulic acid shows a potent ability to remove reactive oxygen species (ROS) and inhibits lipid peroxidation. (E)-Ferulic acid exerts both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299. -
Cardiogenol C is a potent and cell permeable inducer of embryonic stem cell differentiation in cardiomyocytes displaying an Ec50 of 100nm.
- Cardiogenol C is a diaminopyrimidine compound that induces the differentiation of MHC- (myosin heavy chain) positive cardiomyocytes from embryonic stem cells with an EC50 value of 0.1 uM. Cardiogenol C upregulates cardiac markers and induces cardiac functional properties in lineage-committed progenitor cells.
-
Wnt/beta-catenin inhibitor
Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator with EC50 of 4.61 ?? 1.29 uM; also is an inhibitor of Wnt/beta-catenin signaling. -
Wnt/β-catenin activator
Methyl vanillate, one of the ingredients in Hovenia dulcis Thunb, is a Wnt/β-catenin pathway activator. A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite. - Prodigiosin (Prodigiosine) HCl is a potent proapoptotic agent, and inhibits Wnt/β-catenin pathway.
-
Wnt/β-catenin signaling inhibitor
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. -
Wnt/β-catenin agonist
Wnt/β-catenin agonist 1 is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM. -
FZD4 agonist
FzM1.8 is an allosteric agonist of the Frizzled receptor FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K. -
β-catenin Inhibitor
Zolucatetide is a potent inhibitor of β-catenin, demonstrating an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and the T-cell factor (TCF) transcription factor, leading to inhibited cell proliferation and induced cell cycle arrest in sensitive cell lines. In preclinical studies, Zolucatetide exhibits notable anti-tumor efficacy in xenograft models of colon cancer, specifically in COLO320DM cells with APC and TP53 mutations. This compound is valuable for research focused on colon cancer and related pathways. -
β catenin/BCL9 PPI Inhibitor
ZW4864 is a selective inhibitor of the β-catenin/B-Cell lymphoma 9 (BCL9) protein-protein interaction. It demonstrates potent inhibition with a Ki value of 0.76 μM and an IC50 of 0.87 μM. This compound is valuable for research applications targeting the Wnt signaling pathway in cancer biology, particularly in studies related to tumor progression and development. -
β-catenin Inhibitor
NRX-252262 is a potent β-catenin inhibitor that enhances the interaction between β-catenin and its E3 ligase, SCFβ-TrCP, facilitating the degradation of mutant β-catenin. With an EC50 of 3.8 nM, it serves as a valuable tool for studying the Wnt signaling pathway and its implications in various cancers and developmental processes. This compound is useful in research applications focused on β-catenin dysregulation and therapeutic strategies targeting Wnt-mediated pathways. -
β-Catenin Inhibitor
β-Catenin-IN-2 is a potent inhibitor of β-catenin, a key regulator in the Wnt signaling pathway. This compound demonstrates significant biological activity in various cancer models, particularly in the study of colorectal cancer. Research applications include investigating the role of β-catenin in tumorigenesis and exploring potential therapeutic interventions targeting this pathway. -
β-catenin Inhibitor
β-catenin-IN-3 is a selective inhibitor of β-catenin, targeting a cryptic allosteric modulation site with a binding affinity of K D 54.96 nM. This compound effectively reduces the viability of β-catenin-driven cancer cells by promoting degradation of β-catenin through the proteasome pathway. β-catenin-IN-3 is valuable for research applications focused on cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin:β-TrCP Interaction Enhancer
NRX-252114 is a potent enhancer of the β-catenin:β-TrCP interaction, facilitating the binding of phosphorylated β-catenin peptides to the E3 ubiquitin ligase SCFβ-TrCP. With an EC50 of 6.5 nM and a Kd of 0.4 nM, this compound significantly boosts the degradation of mutant β-catenin. NRX-252114 is useful in research applications focused on the Wnt signaling pathway and its implications in cancer biology and developmental processes. -
β-catenin:β-TrCP Interaction Enhancer
NRX-103094 is an enhancer of the β-catenin:β-TrCP interaction, specifically targeting the binding of phospho-Ser33/Ser37 β-catenin to its E3 ligase, SCFβ-TrCP. With an EC50 of 62 nM and a Kd of 0.6 nM, NRX-103094 facilitates this critical protein-protein interaction, making it a valuable tool for research into Wnt signaling pathways and related cellular processes. Its ability to modulate β-catenin stability can aid investigations into various aspects of cellular biology, including cancer research and developmental biology. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin agonist 2 is a potent activator of the Wnt/β-catenin signaling pathway. This compound effectively stimulates Wnt signaling, making it a valuable tool for investigating the molecular mechanisms underlying diseases associated with aberrant signal transduction. Researchers can utilize this reagent in studies focused on developmental biology, cancer research, and regenerative medicine, where modulation of the Wnt pathway plays a critical role. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
β catenin/BCL9 PPI Inhibitor
ZW4864 free base is a selective inhibitor of the β-catenin/BCL9 protein-protein interaction. It exhibits significant inhibitory activity with a Ki value of 0.76 μM and an IC50 value of 0.87 μM, making it a valuable tool for researching β-catenin signaling pathways. This compound is particularly relevant for studies related to cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin/Tcf PPI Inhibitor
UU-T02 is a selective small-molecule inhibitor targeting the β-catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI), exhibiting a Ki value of 1.36 μM. This compound effectively inhibits canonical Wnt signaling pathways, demonstrating significant potential in suppressing the growth of colorectal cancer cells. Its application in research is valuable for understanding Wnt-related mechanisms in cancer biology and developing therapeutic strategies. -
β-catenin/BCL9 Inhibitor
Antitumor agent-172 is a selective β-catenin/BCL9 inhibitor, demonstrating an IC50 of 3.92 μM and a high binding affinity with a Kd of 82 nM. This compound activates T cells and enhances antigen presentation, thereby exhibiting significant antitumor efficacy. It also displays favorable pharmacokinetic properties in mouse models, making it a valuable tool for cancer research and therapy. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin Agonist 3 is a potent activator of the Wnt/β-catenin signaling pathway. This compound enhances β-catenin-mediated transcriptional activity, making it valuable for research related to bone density disorders such as osteoporosis. Its application in cellular and animal models provides insights into the molecular mechanisms underlying Wnt signaling and offers potential therapeutic avenues for bone-related diseases. -
β-catenin/BCL9 Inhibitor
Antitumor agent-171 is a potent inhibitor of the β-catenin/BCL9 interaction, demonstrating an IC50 value of 1.61 μM. This compound exhibits a strong binding affinity to β-catenin, with a Kd of 0.63 μM, and effectively inhibits the expression of the axin2 gene with an IC50 of 0.84 μM. Additionally, Antitumor agent-171 reduces cell viability in HCT116 cells at an IC50 of 4.39 μM. Its ability to activate T cells and enhance antigen presentation underscores its potential in antitumor applications, with favorable pharmacokinetic properties observed in mouse models. -
β-catenin/Tcf PPI Inhibitor
UU-T01 is a selective inhibitor of the β-catenin/T-cell factor 4 (Tcf) protein-protein interaction, exhibiting a Ki value of 3.14 µM. This compound directly binds to β-catenin, with a dissociation constant (KD) of 0.531 µM. UU-T01 is valuable in research focused on Wnt signaling pathways and their implications in cellular processes such as proliferation and differentiation, offering potential insights into cancer biology and related disorders. -
β-catenin:β-TrCP Interaction Enhancer
NRX-1933 is a β-catenin:β-TrCP interaction enhancer that serves as a molecular glue, facilitating the ubiquitination and subsequent degradation of mutated β-catenin. This compound is particularly relevant for research involving the aberrant activation of the Wnt/β-catenin signaling pathway, providing insights into tumor progression and potential therapeutic strategies. Its ability to promote targeted degradation of dysregulated β-catenin makes NRX-1933 a valuable tool for studies on cancer biology and treatment development. -
β-catenin:β-TrCP Interaction Enhancer
NRX-103095 is an enhancer of the interaction between β-catenin and its E3 ubiquitin ligase, SCFβ-TrCP. This compound significantly increases the binding affinity of the phosphorylated β-catenin peptide (pSer33/Ser37) for β-TrCP, exhibiting an EC50 of 163 nM. NRX-103095 is valuable for research applications focused on the Wnt/β-catenin signaling pathway and its implications in various cellular processes and diseases. -
β-catenin:β-TrCP Interaction Enhancer
NRX-2663 is an enhancer of the β-catenin:β-TrCP interaction, specifically targeting the binding of β-catenin to its E3 ubiquitin ligase, SCFβ-TrCP. This compound improves the affinity of β-catenin peptides for β-TrCP, demonstrating an EC50 of 22.9 μM and a Kd of 54.8 nM. NRX-2663 is valuable for research into the regulation of the Wnt signaling pathway and its implications in various cancers and developmental processes. -
β-catenin/Tcf PPI Inhibitor
β-catenin-IN-37 is a selective inhibitor of the β-catenin/T-cell factor (Tcf) protein-protein interaction. This compound effectively disrupts canonical Wnt signaling, exhibiting inhibitory activity against colorectal cancer cell lines SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively. β-catenin-IN-37 is valuable for studying Wnt signaling pathways and their implications in cancer research. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
β-catenin/TCF Signaling Inhibitor
CCT031374 hydrobromide is a potent inhibitor of the β-catenin/TCF signaling pathway. It effectively disrupts TCF-dependent transcription of target genes associated with the Wnt signaling cascade. CCT031374 demonstrates significant antitumor activity, making it valuable for research in cancer biology and therapeutic development targeting aberrant Wnt signaling.
